


PT-141 is designed to support sexual desire and intimacy for people who feel their interest in sex is lower than it used to be. FDA-approved bremelanotide is indicated for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
It may help support feeling more responsive and engaged in intimate moments. Clinical literature reports improvement in sexual desire and related distress with bremelanotide treatment in the studied population.
PT-141 is often chosen by people who want support with confidence, connection, and a better overall intimate experience.

PT-141 works through melanocortin pathways in the central nervous system rather than working like a typical blood-flow-focused treatment.

It is used by people looking for support with sexual desire, responsiveness, and feeling more interested in intimacy. Clinical studies of bremelanotide in premenopausal women with HSDD found improvements in desire and distress measures.

PT-141 is designed for people who want support with desire, arousal, and confidence in intimate settings as part of provider-guided care.

You fill out a brief medical intake about your goals, symptoms, and health history. This helps your provider determine if PT-141 is appropriate for you.
A licensed clinician reviews your case and creates a tailored PT-141 plan based on your needs.
If approved, your PT-141 medication is prepared by a U.S.-based compounding pharmacy and delivered directly to your door.
Ask questions, request adjustments, and get support anytime from your care team.
Weight-loss solutions designed to transform and sustain
Longevity medications designed to extend and enhance